Table 2 Summary of multivariable assessment for progression free survival (PFS).

From: Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients

Parameter

Hazard ratio (95% CI)

p value

Autograft CPC status

 Positive vs. Negative

2.03 (1.48, 2.80)

<0.001

ISS

 II vs. I

1.47 (1.05, 2.06)

0.026

 III vs. I

1.55 (1.09, 2.21)

0.014

KPS

 ≥90 vs. <90

0.95 (0.73, 1.24)

0.72

HCT-CI

 >3 vs. ≤3

1.19 (0.88, 1.62)

0.25

Prior response

 PR or worse vs. VGPR or better

1.24 (0.93, 1.64)

0.14

Prior MRD response

 Positive vs. Negative

1.61 (1.17, 2.22)

0.004

Maintenance therapya

 Yes vs. No

1.20 (0.86, 1.66)

0.28

Positive bag infusedb

 Yes vs. No

2.72 (1.82, 4.08)

<0.001

Degree of autograft MRD positivity – averageb

1.50 (1.17, 1.90)

0.001

  1. CI Confidence interval, MRD Minimal residual disease, ISS international staging system, KPS Karnofsky performance status, HCT-CI Hematopoietic cell transplant comorbidity index.
  2. aIncluded in the model as a time-dependent covariate.
  3. bReplaces autograft CPC status in separate multivariable models; HCT-CI, prior response, and prior MRD response were included in this model.
Back to article page